Lin BioScience, Inc.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.linbioscience.com

Country

Taiwan

Exchange

Taipei Exchange

Taipei, Taiwan

Lin BioScience, Inc., a drug development company develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD.

Its portfolio also includes LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers, LBS-002, an anti-tubulin to treat primary and metastatic brain tumors, and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.

Key Stats

52-Week Range

NT$148.00NT$773.00

Beta0.16

Trailing P/EN/A

Forward P/EN/A

Trailing EPS-16.57

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.